Publications by authors named "Ola Alkhozondar"
Background: Coronavirus disease 2019 (COVID-19) pandemic has resulted in unprecedented pressure on healthcare systems and led to widespread utilization of telemedicine or telehealth services. Combined with teleclinics, using drive-up fingerstick International normalized ratio (INR) testing was recommended to decrease exposure risk of anticoagulation patients.
Objective: To evaluate the impact of transitioning from clinic-based anticoagulation management services to drive-up and phone-based services during COVID-19 pandemic in Qatar.
IMPORTANCE trial: a provisional study-design of a single-center, phase II, double-blinded, placebo-controlled, randomized, 4-week study to compare the efficacy and safety of intranasal esketamine in chronic opioid refractory pain.
Mauricio Fernandes Magdalena Schelotto Philipp Maximilian Doldi Giovanna Milani Abul Andrés Ariza Manzano Ola M J Alkhozondar
F1000Res
June 2021
Article Synopsis
- Cancer is the second leading cause of death worldwide, with a high percentage of advanced patients suffering from significant pain, and limited options for chronic pain management.
- Esketamine, a newer drug with better analgesic effects and fewer side effects than traditional opioids, has been FDA-approved for depression but never tested for chronic cancer pain.
- A proposed phase II trial will test intranasal esketamine in 120 participants with chronic opioid refractory pain to assess its effectiveness and safety, aiming to improve pain management and quality of life.